Rapid Response of a <i>BRCA2/TP53/PTEN</i> -Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report
Minggui Pan, Kristen N. Ganjoo, Amer Karam
Abstract
None: Patients with metastatic uterine leiomyosarcoma (uLMS) have poor prognosis due to limited treatment options, especially when disease progresses on doxorubicin and gemcitabine-docetaxel regimens. Here we report a patient whose metastatic uLMS contains a BRCA2 deep deletion as well as TP53 and PTEN deep deletion. The patient responded rapidly to olaparib, a poly (ADP-ribose) polymerase inhibitor, after progressing on gemcitabine-docetaxel, doxorubicin, and temozolomide regimens. This case report shall be helpful to the treatment of other patients with metastatic uLMS that harbors a BRCA2 mutation or deletion.
Topics & Concepts
OlaparibMedicineGemcitabineDocetaxelPTENOncologyInternal medicineDoxorubicinTemozolomideLeiomyosarcomaCancer researchChemotherapyPoly ADP ribose polymerasePI3K/AKT/mTOR pathwayPathologyPolymeraseBiologyGeneBiochemistryApoptosisPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentCAR-T cell therapy research